Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III ma...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Reardon, David A., Herndon, James E., Peters, Katherine, Desjardins, Annick, Coan, April, Lou, Emil, Sumrall, Ashley, Turner, Scott, Sathornsumetee, Sith, Rich, Jeremy N., Boulton, Susan, Lipp, Eric S., Friedman, Henry S., Vredenburgh, James J.
Format: Artigo
Język:Inglês
Wydane: 2011
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3403724/
https://ncbi.nlm.nih.gov/pubmed/21997879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0740-0
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy